Bengt Westermark - Genetic Mutations

Author Information

Bengt Westermark is affiliated with the Department of Immunology, Genetics and Pathology, and Science for Life Laboratory at the Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. His research primarily focuses on the molecular and cellular mechanisms underlying cancer, particularly glioblastoma, and the role of various signaling pathways and cellular interactions in tumorigenesis and therapy resistance.

Research Contributions

Bengt Westermark has made significant contributions to the field of cancer research, particularly in understanding glioblastoma. His recent work includes studying the impact of BMP signaling on tumorigenesis and the role of DNA methyltransferase 3A in glioma-initiating cell properties. He has also explored glioblastoma heterogeneity, immune cell presence in different glioblastoma subtypes, and the interaction between neural stem cells and glioblastoma cells. Additionally, his research has looked into the synergistic effects of BET and Aurora Kinase A inhibitors, the reactivity of astrocytes in therapy resistance, and the role of platelet-derived growth factor in tumorigenesis.

Aliases

Bengt Westermark is also known by the following aliases: B Westermark and B. Westermark.

Publication and Citation Metrics

Metric	Value
Total Citation Count	29,635
H-index	87
Total Paper Count	407

Publications:

PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma‐initiating cell properties via DNA methyltransferase 3A

DOI: 10.1002/1878-0261.13051

Year: 2021

Modeling glioblastoma heterogeneity as a dynamic network of cell states

DOI: 10.15252/msb.202010105

Year: 2021

A human cell type similar to murine central nervous system perivascular fibroblasts.

DOI: 10.1016/j.yexcr.2021.112576

Year: 2021

Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors

DOI: 10.1080/2162402X.2019.1655360

Year: 2019

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells

DOI: 10.1038/s41419-019-2120-1

Year: 2019

Live detection of neural stem and glioblastoma cells by an oligothiophene derivative

DOI: 10.1101/579185

Year: 2019

Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity

DOI: 10.1002/path.5317

Year: 2019

Role of Platelet-Derived Growth Factor in Autocrine and Paracrine Stimulation of Normal and Malignant Cells

DOI: 10.1201/9780429276064-3

Year: 2019

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden

DOI: 10.1080/0284186X.2017.1337926

Year: 2018

Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis

DOI: 10.1111/joim.12690

Year: 2018

What Are the Successes of Gene Therapy?

Which Genes are Involved in Autism Spectrum Disorder?

How is Sickle Cell Anemia Diagnosed?

What Are the Ethical Considerations for CRISPR Technology?

How does Research Advance Treatment?

What Are the Different Types of Mutations?

Can Synonymous Codons Contribute to Disease?

Can Insertion Mutations Be Repaired?

How Do Genetic Mutations Contribute to Heart Disease?

What are Immunotherapies?

Partnered Content Networks

Relevant Topics